Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX3901 in Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT07416695Phase 1Recruiting
- Sponsor
- Henlius
- Start
- Apr 2026
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, T-cell Engagers, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HLX3901 in small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) (2 arms), sponsored by Henlius. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 4 weeks and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
HLX3901
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT07416695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416695.